FGF23 and chronic kidney disease: Milovanova and coworkers published a comparative study of LPD supplemented with KA and LPD alone in CKD 3b–4 stage patients in relation to serum klotho and FGF-23 levels, key markers of cardiovascular complications and CKD progression.